Cumberland Pharmaceuticals (NASDAQ:CPIX) issued its earnings results on Wednesday. The specialty pharmaceutical company reported $0.09 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.01 by $0.08, Fidelity Earnings reports. The business had revenue of $13.68 million during the quarter, compared to the consensus estimate of $11.34 million. Cumberland Pharmaceuticals had a positive return on equity of 6.61% and a negative net margin of 7.45%.
NASDAQ CPIX opened at $3.60 on Friday. The company has a market cap of $54.66 million, a price-to-earnings ratio of 17.14 and a beta of 0.30. Cumberland Pharmaceuticals has a 52 week low of $3.45 and a 52 week high of $6.99. The business has a 50 day moving average price of $4.33 and a 200-day moving average price of $4.99. The company has a quick ratio of 1.88, a current ratio of 2.35 and a debt-to-equity ratio of 0.39.
A number of equities research analysts have weighed in on the company. B. Riley reiterated a “buy” rating on shares of Cumberland Pharmaceuticals in a report on Thursday. TheStreet downgraded Cumberland Pharmaceuticals from a “c-” rating to a “d+” rating in a report on Friday, March 13th. Finally, Zacks Investment Research upgraded Cumberland Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.00 price objective for the company in a report on Thursday.
Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. It offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating hyponatremia; Ethyol injection for the reduction of xerostomia; Totect injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy; and Vibativ injection, for the treatment of certain serious bacterial infections.
Featured Article: Does the Dogs of the Dow strategy work?
Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.